PepGen (NASDAQ:PEPG) Major Shareholder Science Enterprises Plc Oxford Buys 200,000 Shares

PepGen, Inc. (NASDAQ:PEPG) major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the firm’s stock in a transaction on Tuesday, September 30th. The stock was bought at an average price of $3.20 per share, with a total value of $640,000.00. Following the completion of the purchase, the insider owned 4,955,388 shares of the company’s stock, valued at approximately $15,857,241.60. This represents a 4.21% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

PepGen Trading Up 1.9%

NASDAQ:PEPG opened at $4.71 on Thursday. PepGen, Inc. has a 1-year low of $0.88 and a 1-year high of $9.94. The firm has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $1.54. The stock has a market capitalization of $154.49 million, a PE ratio of -1.59 and a beta of 1.92.

PepGen (NASDAQ:PEPG) last released its earnings results on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.15. On average, equities analysts predict that PepGen, Inc. will post -2.73 earnings per share for the current fiscal year.

Institutional Trading of PepGen

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in PepGen in the 1st quarter valued at $25,000. ADAR1 Capital Management LLC bought a new stake in shares of PepGen in the first quarter valued at about $29,000. Rangeley Capital LLC boosted its position in shares of PepGen by 133.3% in the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after acquiring an additional 20,000 shares during the period. Marshall Wace LLP bought a new stake in shares of PepGen in the second quarter valued at about $44,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of PepGen during the 2nd quarter worth approximately $81,000. 58.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on PEPG. Wedbush lifted their price target on PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th. HC Wainwright lifted their target price on PepGen from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Guggenheim reiterated a “buy” rating and set a $6.00 target price on shares of PepGen in a research note on Wednesday, September 24th. Finally, Stifel Nicolaus lifted their price objective on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.40.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.